The Scientific Advisory Board is led by Thomas Stossel, MD, Board Member and Gelsolin Discover
Po-Shun Lee, MD (Founding Scientist and Scientific Advisor)
Po-Shun Lee is pulmonary and critical care physician who is currently the Chief Medical Officer and Senior Vice President, Clinical Development at Proteostasis Therapeutics. Prior to joining Proteostasis, Dr. Lee was Translational Medical Expert at Novartis Institute for Biomedical Research and Associate Medical Director at Vertex Pharmaceuticals, where he worked on phase 2 and phase 3 studies developing Vertex’ products for cystic fibrosis. Previously, Dr. Lee was an Instructor in Medicine at Harvard Medical School, attending pulmonologist/intensivist in the Pulmonary and Critical Care Division and the Medical Director for the Pulmonary Function Lab at the Brigham & Women’s Hospital.
Dr. Lee worked in Dr. Stossel’s lab for 10 years where he was responsible for pGSN assay studies and rhu-pGSN preclinical animal models. Dr. Lee has presented at the American Thoracic Society International Meeting on the subject of pGSN’s clinical and scientific implications. In 2004, Dr. Lee received an award from the New England Respiratory Research Competition and Awards program for his research on pGSN.
Dr. Lee received his undergraduate degree from Johns Hopkins University and his medical degree from the University of Pennsylvania School of Medicine. He completed his residency training at the Brown University Internal Medicine Residency Program and his subspecialty training at the Harvard Combined Pulmonary and Critical Care Fellowship.
Ananth Karumanchi, MD (Scientific Advisor)
S. Ananth Karumanchi, MD is a Professor of Medicine at Harvard Medical School, Boston and attending physician in Nephrology at Beth Israel Deaconess Medical Center. His current research focuses on the role of angiogenic growth factors and inhibitors in the pathogenesis of preeclampsia and other cardiovascular diseases. He has received prestigious awards from several societies including the highest recognitions from the International Society for the Study of Hypertension in Pregnancy – Chesley Award (2010) and Outstanding Investigator Award (2010) from the American Federation for Medical Research. He was elected to the American Society for Clinical Investigation in 2007 and the Association of American Physicians in 2015. Dr. Karumanchi’s research has been funded by Howard Hughes Medical Institute, American Heart Association, Gates Foundation, and the National Institutes of Health.
Dr. Karumanchi received his medical degree in 1992 from the University of Madras, India. Dr. Karumanchi completed his residency in Internal Medicine at Henry Ford Hospital, Detroit, MI, and a fellowship in Nephrology at Beth Israel Deaconess Medical Center, Boston. MA. Dr. Karumanchi also underwent training in basic research in the area of angiogenesis for 4 years at the Beth Israel Deaconess Medical Center prior to starting his independent research program.
Lester Kobzik, MD (Scientific Advisor)
Lester Kobzik is a Professor of Pathology at the Harvard Medical School and the Harvard T. H. Chan School of Public Health. His research interests center on lung disease and how the lung defends itself against inhaled toxic and infectious challenges. His laboratory studies scavenger receptors on lung macrophages and how they function to remove potentially harmful if inhaled particulates and bacteria. He is also actively engaged in studies of infectious agents, including use of functional genomic screening to identify novel pathways and therapeutic leads. He has authored over 200 research publications in the area of lung pathobiology, and has served on numerous grant and scientific review panels for the NIH, EPA and other research organizations.
Dr. Kobzik received his undergraduate degree and medical degree from Tufts University. He completed residency training in anatomic pathology at the Brigham and women’s Hospital, then joined the faculty there and at the Harvard Medical and Public Health Schools.
Ravi Thadhani, MD, MPH (Scientific Advisor)
Ravi Thadhani, MD, MPH, is the Director of Clinical Research in Nephrology at Massachusetts General Hospital (MGH), and an Associate Professor of Medicine at Harvard Medical School. Dr. Thadhani directs academic courses at The Massachusetts Institute of Technology, MGH, and Harvard Medical School. He has served as a reviewer for, and has been published in, several journals, including the New England Journal of Medicine and Lancet. He is an active member of the National Kidney Foundation and the clinical research section of the American Society of Nephrology. He reviews grants for these organizations as well as for the National Institutes of Health. His research interests include hypertension and diabetes in pregnancy, and dialysis mortality, the latter with a focus on the role of Vitamin D. He has greatly contributed to the understanding of plasma gelsolin’s ability to accurately predict mortality in end-stage renal disease.
Dr. Thadhani received his BS degree summa cum laude from The University of Notre Dame, his MD from the University of Pennsylvania, and his MPH from The Harvard School of Public Health. He spent a year as Chief Medical Resident at MGH, where he completed his training with a specialization in nephrology.